NASDAQ: EXEL - Exelixis

Yield per half year: +34.57%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Exelixis

Extended chart Simple chart
Financial Markets by TradingView

About Exelixis

Exelixis, Inc. - биотехнологическая компания, специализирующаяся на разработке перспективных низкомолекулярных препаратов для лечения рака и других серьёзных заболеваний, в том числе поражения почек, рака щитовидной железы и прогрессирующей меланомы. Кроме того, компания создаёт стратегические партнёрства с другими фармацевтическими и биотехнологическими компаниями.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2000-04-07
ISIN US30161Q1040
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.exelixis.com
Цена ао 37.71
Change price per day: +2.47% (34.46)
Change price per week: +2.14% (34.57)
Change price per month: -5.08% (37.2)
Change price per 3 month: -1.97% (36.02)
Change price per half year: +34.57% (26.24)
Change price per year: +54.8% (22.81)
Change price per 3 year: +81.17% (19.49)
Change price per 5 year: +75.06% (20.17)
Change price per 10 year: +352.69% (7.8)
Change price per year to date: +1.79% (34.69)
All parameters

Underestimation

Title Value Grade
P/S 4.2 4
P/BV 3.4 5
P/E 37.04 5
EV/EBITDA 38.77 2
Total: 5.38

Efficiency

Title Value Grade
ROA, % 7.06 2
ROE, % 9.18 3
Total: 3.17

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0.9661 9
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 89.11 9
Yield Ebitda, % -46.79 0
Yield EPS, % -36.64 0
Total: 1.8
More

Institutions Volume Share, %
Blackrock Inc. 36014432 11.88
Vanguard Group Inc 31671090 10.45
Farallon Capital Management Llc 26634500 8.78
Renaissance Technologies, LLC 15615716 5.15
State Street Corporation 13032818 4.3
JP Morgan Chase & Company 7741589 2.55
Geode Capital Management, LLC 5145318 1.7
Morgan Stanley 4774731 1.57
Dimensional Fund Advisors LP 4560517 1.5
Stephens Investment Management Group 4106664 1.35

ETFShare, %Profitability for 1 year, %Dividends, %
Future Tech ETF 0.73116 426.34 0.8416
Principal Healthcare Innovators ETF 0.73116 618.5 0.8416
Syntax Stratified MidCap ETF 0.51652 17.66 1.56212
iShares Morningstar Small-Cap Growth ETF 0.3278 596.94 0.72598
iShares Morningstar Small-Cap ETF 0.16543 391.25 1.60498
0.5410.141.11



Head Job title Payment Year of birth
Dr. Stelios Papadopoulos Ph.D. Co-Founder & Chair of the Board 109k 1948 (77 years)
Mr. Christopher J. Senner Executive VP & CFO 1.09M 1968 (57 years)
Ms. Susan T. Hubbard Executive Vice President of Public Affairs & Investor Relations N/A
Dr. Michael M. Morrissey Ph.D. CEO, President & Director 2.31M 1961 (64 years)
Mr. Jeffrey J. Hessekiel J.D. Executive VP, General Counsel & Secretary 959.68k 1969 (56 years)
Dr. Dana T. Aftab Ph.D. Executive VP of Discovery and Translational Research & Chief Scientific Officer N/A 1964 (61 year)
Mr. Patrick J. Haley M.B.A. Executive Vice President of Commercial 844.64k 1976 (49 years)
Dr. Anne Champsaur M.D. Senior Vice President of Drug Safety N/A
Dr. Amy C. Peterson M.D. Executive VP, Product Development & Medical Affairs and Chief Medical Officer 1967 (58 years)
Dr. William Berg M.D. Senior Vice President of Medical Affairs

Address: United States, Alameda, 1851 Harbor Bay Parkway - open in Google maps, open in Yandex maps
Website: http://www.exelixis.com